These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 39121982)

  • 1. Dapagliflozin alleviates right heart failure by promoting collagen degradation by reducing ROS levels.
    Liu DD; Liu XL; Zheng TF; Li X; Zhao YC; Pan JC; Yuan C; Wang QQ; Zhang M
    Eur J Pharmacol; 2024 Oct; 981():176875. PubMed ID: 39121982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dapagliflozin: a sodium-glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling.
    Zhang Y; Lin X; Chu Y; Chen X; Du H; Zhang H; Xu C; Xie H; Ruan Q; Lin J; Liu J; Zeng J; Ma K; Chai D
    Cardiovasc Diabetol; 2021 Jun; 20(1):121. PubMed ID: 34116674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPKα/TGF-β/Smad signalling in type 2 diabetic rats.
    Tian J; Zhang M; Suo M; Liu D; Wang X; Liu M; Pan J; Jin T; An F
    J Cell Mol Med; 2021 Aug; 25(16):7642-7659. PubMed ID: 34169635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dapagliflozin reduces the vulnerability of rats with pulmonary arterial hypertension-induced right heart failure to ventricular arrhythmia by restoring calcium handling.
    Wu J; Liu T; Shi S; Fan Z; Hiram R; Xiong F; Cui B; Su X; Chang R; Zhang W; Yan M; Tang Y; Huang H; Wu G; Huang C
    Cardiovasc Diabetol; 2022 Sep; 21(1):197. PubMed ID: 36171554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dapagliflozin Suppresses ER Stress and Improves Subclinical Myocardial Function in Diabetes: From Bedside to Bench.
    Shih JY; Lin YW; Fisch S; Cheng JT; Kang NW; Hong CS; Chen ZC; Chang WT
    Diabetes; 2021 Jan; 70(1):262-267. PubMed ID: 33115828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dapagliflozin Improves Cardiac Hemodynamics and Mitigates Arrhythmogenesis in Mitral Regurgitation-Induced Myocardial Dysfunction.
    Lin YW; Chen CY; Shih JY; Cheng BC; Chang CP; Lin MT; Ho CH; Chen ZC; Fisch S; Chang WT
    J Am Heart Assoc; 2021 Apr; 10(7):e019274. PubMed ID: 33749310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dapagliflozin dampens liver fibrosis induced by common bile duct ligation in rats associated with the augmentation of the hepatic Sirt1/AMPK/PGC1α/FoxO1 axis.
    Hassan HA; Nageeb MM; Mohammed HO; Samy W; Fawzy A; Afifi R; Abbas NAT
    Toxicol Appl Pharmacol; 2024 Aug; 489():116991. PubMed ID: 38871090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of extracellular matrix stiffness on efficacy of Dapagliflozin for diabetic cardiomyopathy.
    Zhu T; Ye Z; Song J; Zhang J; Zhao Y; Xu F; Wang J; Huang X; Gao B; Li F
    Cardiovasc Diabetol; 2024 Jul; 23(1):273. PubMed ID: 39049086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor.
    Ye Y; Bajaj M; Yang HC; Perez-Polo JR; Birnbaum Y
    Cardiovasc Drugs Ther; 2017 Apr; 31(2):119-132. PubMed ID: 28447181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dapagliflozin Attenuates Cardiac Remodeling in Mice Model of Cardiac Pressure Overload.
    Shi L; Zhu D; Wang S; Jiang A; Li F
    Am J Hypertens; 2019 Apr; 32(5):452-459. PubMed ID: 30689697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced
    Hodrea J; Balogh DB; Hosszu A; Lenart L; Besztercei B; Koszegi S; Sparding N; Genovese F; Wagner LJ; Szabo AJ; Fekete A
    Am J Physiol Renal Physiol; 2020 Apr; 318(4):F1017-F1029. PubMed ID: 32116017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SGLT2 inhibitor dapagliflozin attenuates cardiac fibrosis and inflammation by reverting the HIF-2α signaling pathway in arrhythmogenic cardiomyopathy.
    Yang Z; Li T; Xian J; Chen J; Huang Y; Zhang Q; Lin X; Lu H; Lin Y
    FASEB J; 2022 Jul; 36(7):e22410. PubMed ID: 35713937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats.
    Durak A; Olgar Y; Degirmenci S; Akkus E; Tuncay E; Turan B
    Cardiovasc Diabetol; 2018 Nov; 17(1):144. PubMed ID: 30447687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antifibrotic response of cardiac fibroblasts in hypertensive hearts through enhanced TIMP-1 expression by basic fibroblast growth factor.
    Kinoshita T; Ishikawa Y; Arita M; Akishima-Fukasawa Y; Fujita K; Inomata N; Suzuki T; Namiki A; Mikami T; Ikeda T; Yamazaki J; Ishii T; Akasaka Y
    Cardiovasc Pathol; 2014; 23(2):92-100. PubMed ID: 24322055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion.
    Packer M
    Cardiovasc Diabetol; 2019 Oct; 18(1):129. PubMed ID: 31585532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefit of combination therapy with dapagliflozin and eplerenone on cardiac function and fibrosis in rats with non-diabetic chronic kidney disease.
    Soulié M; Stephan Y; Durand M; Lima-Posada I; Palacios-Ramírez R; Nicol L; Lopez-Andres N; Mulder P; Jaisser F
    Sci Rep; 2024 Oct; 14(1):23955. PubMed ID: 39397161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicted Cardiac Hemodynamic Consequences of the Renal Actions of SGLT2i in the DAPA-HF Study Population: A Mathematical Modeling Analysis.
    Yu H; Tang W; Greasley PJ; Penland RC; Boulton DW; Hallow KM
    J Clin Pharmacol; 2021 May; 61(5):636-648. PubMed ID: 33091173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.
    Arow M; Waldman M; Yadin D; Nudelman V; Shainberg A; Abraham NG; Freimark D; Kornowski R; Aravot D; Hochhauser E; Arad M
    Cardiovasc Diabetol; 2020 Jan; 19(1):7. PubMed ID: 31924211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autophagy mechanism of right ventricular remodeling in murine model of pulmonary artery constriction.
    Qipshidze N; Tyagi N; Metreveli N; Lominadze D; Tyagi SC
    Am J Physiol Heart Circ Physiol; 2012 Feb; 302(3):H688-96. PubMed ID: 22101525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SGLT2 inhibitor dapagliflozin prevents atherosclerotic and cardiac complications in experimental type 1 diabetes.
    Hodrea J; Saeed A; Molnar A; Fintha A; Barczi A; Wagner LJ; Szabo AJ; Fekete A; Balogh DB
    PLoS One; 2022; 17(2):e0263285. PubMed ID: 35176041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.